



**Vineet Laboratories Limited**

Regd. Office: SY. No. 11/A3, Saheb Nagar, Kurdu Vill, Chintal Kunta, Eshwaramma Nilayam, L B Nagar Hyderabad.  
CIN- L24304TG2016PLC112888  
Phone: 040-24128833; Email Id: cs@vineetlabs.co.in; Website: vineetlabs.co.in

November 11, 2023

To  
The General Manager  
Department of Corporate Services  
**BSE Limited**  
P.J. Towers, Dalal Street,  
Mumbai-400 001  
Scrip Code – 543298

To  
The Manager  
Listing Department  
**National Stock Exchange of India Limited**  
Exchange Plaza, 5<sup>th</sup> Floor, Plot No – C/1,  
G Block, Bandra Kurla Complex  
Bandra (East), Mumbai -400 051  
Scrip Code - VINEETLAB

Dear Sir/Ma'am,

**Sub: Revised Outcome of Board Meeting held on Friday, November 10, 2023 as required under Regulation 30 of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015**

In continuation to our earlier announcement dated November 10, 2023 relating to the outcome of meeting of Board of Directors held on November 10, 2023 wherein we have submitted:

- the Unaudited Financial Results of the company for the Second Quarter and the Half year ended on September 30, 2023 along with the Limited Review Report submitted by the Statutory Auditors, and
- the appointment of Mr. Rameshkumar Bandari (Membership No: A24519) as the Company Secretary and Compliance Officer of the Company with effect from November 10, 2023.

This is to inform you that in the said announcement we have inadvertently enclosed the Cash Flow Statement, which was not in line in with the Profit & Loss Account and the Statement of Assets and Liabilities.

Hence, in compliance with Regulation 33 of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 we are herewith resubmitting complete set of Un-audited financial results along with Limited Review Report for the Second quarter and the Half year ended on September 30, 2023.

We sincerely regret the inconvenience and request your office to kindly take on records this resubmission of results.

The details that need to be disclosed of the events under Regulation 30 of SEBI LODR Regulations read with SEBI Circular No. CIR/CFD/CMD/4/2015 dated September 9, 2015 and SEBI/HO/CFD/CFD-PoD-1/P/CIR/2023/123 dated July 13, 2023 are mentioned in Annexure I to this outcome.

The Board Meeting commenced at 3:00 PM and concluded at 04:00 PM on November 10, 2023.

Kindly take this information on records.

Thanking you,  
Best Regards,

For Vineet Laboratories Limited

Satyanarayanaraju Bhupathiraju  
Whole-Time Director and CFO  
DIN: 02697880





**Vineet Laboratories Limited**

Regd. Office: SY. No. 11/A3, Saheb Nagar, Kurdu Vill, Chintal Kunta, Eshwaramma Nilayam, L B Nagar Hyderabad.  
CIN- L24304TG2016PLC112888  
Phone: 040-24128833; Email Id: cs@vineetlabs.co.in; Website: vineetlabs.co.in

Annexure-1

**Appointment of Mr. Rameshkumar Bandari (M.No: A24519) as the Company Secretary and Compliance Officer of the Company**

Name in Full	Mr. Rameshkumar Bandari (DIN: 10294920)
Reason for change viz. appointment, resignation, removal, death or otherwise	Appointment as the Company Secretary and Compliance Officer of the Company
Date of Appointment & Terms of Appointment	Appointed as the Company Secretary and Compliance Officer w.e.f. November 10, 2023 at a remuneration of Rs. 25,000 per month
Brief Profile	<p>Educational Qualification:</p> <ul style="list-style-type: none"><li>• Bachelors in Commerce from Osmania University</li><li>• Associate Company Secretary from the Institute of Company Secretaries of India.</li><li>• Bachelor in Law from the Osmania University</li></ul> <p>Experience: Total 13 years of experience as a Company Secretary of Private and Listed Companies</p>

**VINEET LABORATORIES LIMITED**  
CIN:L24304TG2016PLC112888

SY. No. 11/A3, Eshwaramma Nilayam, Saheb Nagar, Kurdu Vill, Chintal Kunta, LB Nagar, Hyderabad, Telangana-500074, India.

**Statement of Unaudited Financial Results for the quarter and half year ended 30 September 2023**

(Amount in Indian rupees lakhs, except share data and where otherwise stated)

S No	Particulars	Quarter ended			Half year ended		Year ended
		Quarter ended 30 September 2023	Quarter ended 30 June 2023	Quarter ended 30 September 2022	Half year ended 30 September 2023	Half year ended 30 September 2022	Year ended 31 March 2023
		Unaudited	Unaudited	Unaudited	Unaudited	Unaudited	Audited
I	a) Net Sales/income from operations	4,337.27	3,752.30	3,950.55	8,089.57	8,832.72	21,229.33
II	b) Other income	1.44	2.55	0.28	3.99	8.74	12.30
III	<b>Total Income (I + II)</b>	<b>4,338.71</b>	<b>3,754.85</b>	<b>3,950.83</b>	<b>8,093.56</b>	<b>8,841.46</b>	<b>21,241.63</b>
VI	<b>Expenses</b>						
	a) Cost of material consumed	3,174.85	3,030.31	3,703.80	6,205.16	7,515.34	16,809.76
	b) Changes in inventories of finished goods, work-in progress and stock-in-trade(increase)/decrease	(131.37)	48.23	(129.56)	(83.14)	(293.36)	423.03
	c) Employee benefits expense	139.65	140.24	124.30	279.89	245.61	600.29
	d) Finance costs	102.46	95.88	61.37	198.34	197.97	338.02
	e) Depreciation and amortisation expenses	61.20	60.86	70.46	122.06	124.68	237.26
	f) Other expenses	737.49	507.55	652.96	1,245.04	1,374.87	2,630.28
	<b>Total expenses</b>	<b>4,084.27</b>	<b>3,883.07</b>	<b>4,483.33</b>	<b>7,967.34</b>	<b>9,165.11</b>	<b>21,038.64</b>
V	<b>Profit/(loss) before exceptional items and tax (III - IV)</b>	<b>254.44</b>	<b>(128.22)</b>	<b>(532.50)</b>	<b>126.22</b>	<b>(323.65)</b>	<b>202.99</b>
VI	Exceptional items	-	-	-	-	-	-
VII	<b>Profit/(loss) before Tax (V - VI)</b>	<b>254.44</b>	<b>(128.22)</b>	<b>(532.50)</b>	<b>126.22</b>	<b>(323.65)</b>	<b>202.99</b>
VIII	<b>Tax expense :</b>						
	a. Current tax	10.48	-	(63.10)	10.48	-	56.02
	b. Deferred tax	2.06	(3.23)	0.44	(1.17)	45.14	21.72
IX	<b>Profit/(loss) for the period (VII-VIII)</b>	<b>241.90</b>	<b>(125.00)</b>	<b>(469.84)</b>	<b>116.91</b>	<b>(368.79)</b>	<b>125.25</b>
X	<b>Other comprehensive income(OCI)</b>						
	A.						
	(i) Items that will not be reclassified subsequently to profit or loss	-	-	-	-	-	-
	(ii) Income tax relating to items that will not be reclassified subsequently to profit or loss	-	-	-	-	-	-
	B.						
	(i) Items that will be reclassified subsequently to profit or loss	-	-	-	-	-	17.99
	(ii) Income tax relating to items that will be reclassified to profit or loss	-	-	-	-	-	(4.53)
	<b>Total other comprehensive income</b>	<b>-</b>	<b>-</b>	<b>-</b>	<b>-</b>	<b>-</b>	<b>13.46</b>
XI	<b>Total comprehensive income for the Period (IX+X)</b>	<b>241.90</b>	<b>(125.00)</b>	<b>(469.84)</b>	<b>116.91</b>	<b>(368.79)</b>	<b>138.71</b>
XII	<b>Paid-up Equity Share capital (Face Value of Rs. 10/- per share)</b>	<b>921.90</b>	<b>921.90</b>	<b>921.90</b>	<b>921.90</b>	<b>921.90</b>	<b>921.90</b>
XIII	<b>Other Equity</b>	<b>-</b>	<b>-</b>	<b>-</b>	<b>-</b>	<b>-</b>	<b>2,446.45</b>
XIV	<b>Earnings per equity share (of Rs. 10/- each) (not annualised for the quarters)</b>						
	(i) Basic	2.62	(1.36)	(5.10)	1.27	(4.00)	1.36
	(ii) Diluted.	2.62	(1.36)	(5.10)	1.27	(4.00)	1.36

**Notes**

- The financial results of the company have been prepared in accordance with Indian Accounting Standards (Ind AS) notified under the Companies (Indian Accounting Standards) Rules, 2015 as amended by the Companies (Indian Accounting Standards) (Amendment) Rules 2016.
- The above unaudited results have been reviewed by the Audit Committee of the board and approved by the Board of Directors of the Company at their meeting held on 10 November 2023.
- The Statutory Auditors of the Company have carried out the limited review of the above unaudited financial results and their report has been placed before the board at the said meeting as required under Regulation 33 of SEBI (LODR) Regulations, 2015.
- The company operates in one reportable business segment i.e. Active pharmaceuticals ingredient and intermediates. Hence segmental reporting as per Ind AS 108 is not applicable.
- The results for the quarter and half year ended 30 September 2023 are also available on website of BSE Limited, NSE Limited and on the Company's website.
- Figures for the previous periods have been rearranged/ reclassified wherever necessary to conform to the current period presentation.

Date: 10-11-2023  
Place: Hyderabad.



For and on Behalf of Board of Directors

BH.Satyanarayana Raju  
Wholetime Director  
2697880

**VINEET LABORATORIES LIMITED**  
**CIN:L24304TG2016PLC112888**

Regd Office : SY . No. 11/A3, Saheb nagar, Kurdu Vill, Chintal Kunta, Eshwaramma Nilayam, L B Nagar, Hyderabad, Telangana-500074, India.  
Un-Audited Statement of Financial Position as at 30 September 2023

Amt in Rs.

	Particulars	Note No.	As at September 30, 2023	As at Mar 31, 2023
<b>I</b>	<b>ASSETS</b>			
1	<b>Non-current assets</b>			
	(a) Property, plant and equipment	2	26,16,09,289	26,64,56,619
	(i) Financial assets			
	(i) Investments	3	16,48,250	13,35,089
	(vi) other Financial assets	6	68,96,781	68,96,781
	(k) Other non-current asset	8	94,50,809	91,72,321
	<b>Total non-current assets (A)</b>		<b>27,96,05,129</b>	<b>28,38,60,810</b>
2	<b>Current assets</b>			
	(a) Inventories	9	43,52,22,875	46,17,37,737
	(b) Financial assets			
	(i) Trade receivables	4	46,61,14,032	35,16,30,947
	(ii) Cash and cash equivalents	10	62,14,090	63,07,376
	(iv) Bank Balances other than (iii) above		48,68,208	31,59,802
	(iv) other financial assets	6	7,031	2,95,940
	(d) Other current assets	11	2,78,53,808	5,14,99,247
	<b>Total current assets (B)</b>		<b>94,02,80,044</b>	<b>87,46,31,049</b>
	<b>Total assets (A+B+C)</b>		<b>1,21,98,85,172</b>	<b>1,15,84,91,859</b>
<b>II</b>	<b>EQUITY AND LIABILITIES</b>			
1	<b>Equity</b>			
	(a) Equity share capital	13	9,21,90,080	9,21,90,080
	(b) Other equity	14	25,63,34,895	24,46,44,324
	<b>Total equity (A)</b>		<b>34,85,24,975</b>	<b>33,68,34,404</b>
2	<b>Liabilities</b>			
(i)	<b>Non-current liabilities</b>			
	(a) Financial Liabilities			
	(i) Borrowings	15	4,39,39,389	4,84,78,862
	(b) Long term provisions	18	75,44,587	75,44,588
	(c) Deferred tax Liabilities(Net)	7	2,04,19,113	2,05,35,970
	<b>Total non-current liabilities (B)</b>		<b>7,19,03,089</b>	<b>7,65,59,420</b>
(ii)	<b>Current liabilities</b>			
	(a) Financial liabilities			
	(i) Borrowings	15	36,22,55,687	26,24,09,318
	(ii) Trade payables	16		11,76,46,077
	(a) Total outstanding dues of micro and small enterprises		18,69,54,730	23,12,98,242
	(b) Total outstanding dues of creditors other than micro and small enterprises		23,05,98,692	
	(iii) Other financial liabilities	17	33,31,155	26,79,355
	(b) Short term provisions	18	34,03,390	34,03,390
	(c) Other current liabilities	19	85,29,730	12,32,62,585
	(d) Current Tax Laibilities (net)	7	43,83,729	43,99,069
	<b>Total current liabilities (C)</b>		<b>79,94,57,113</b>	<b>74,50,98,036</b>
	<b>Total liabilities (D+B+C)</b>		<b>87,13,60,202</b>	<b>82,16,57,456</b>
	<b>Total equity and liabilities (A+D)</b>		<b>1,21,98,85,176</b>	<b>1,15,84,91,860</b>

The notes are an integral part of the financial statements

For and on behalf of the Board of Directors  
VINEET LABORATORIES LIMITED



Bh. Satyanarayana Raju  
Wohletine Director  
DIN:02697880

Place: Hyderabad  
Date:10.11.2023

**VINEET LABORATORIES LIMITED**  
**CIN:L24304TG2016PLC112888**

Regd Office : SY . No. 11/A3, Saheb nagar, Kurdu Vill, Chintal Kunta, Eshwaramma Nilayam, L B Nagar, Hyderabad, Telangana-500074, India.  
Un-Audited Statement of Profit and Loss and Other Comprehensive Income for the Year ended 30 September 2023

Particulars	NoteNo.	For the period ended Sept 2023	For the year ended March 31, 2023
<b>Continuing Operations</b>			
I Revenue from operations	20	80,89,56,900	2,12,29,33,046
II Other income	21	3,99,198	12,30,137
<b>III Total income</b>		<b>80,93,56,098</b>	<b>2,12,41,63,183</b>
<b>IV Expenses</b>			
(a) Cost of material Consumed	23	62,05,15,862	1,68,09,76,077
(b) Purchase of Stock in Trade			
(c) Changes in stock of finished goods, work-in progress and stock-in-trade	24	(83,14,176)	4,23,03,019
(d) Employee benefits	25	2,79,88,546	6,00,29,343
(e) Finance cost	26	1,98,34,104	3,38,01,876
(f) Depreciation expense	27	1,22,05,764	2,37,26,002
(g) Other expenses	28	12,45,04,050	26,30,27,653
<b>Total expenses (IV)</b>		<b>79,67,34,150</b>	<b>2,10,38,63,970</b>
<b>Profit/(loss) before Share of profit/(loss) of associates / joint ventures, exceptional items and tax (V - VI)</b>		<b>1,26,21,948</b>	<b>2,02,99,213</b>
V		-	-
VI		-	-
<b>VII Profit/(Loss) before exceptional items and tax</b>		<b>1,26,21,948</b>	<b>2,02,99,213</b>
VIII <b>Exceptional itmes</b>		-	-
IX <b>Profit before Tax</b>		<b>1,26,21,948</b>	<b>2,02,99,213</b>
X <b>Tax expense :</b>			
a. Current tax		10,48,235	56,01,754
b. Deferred tax		(1,16,857)	21,72,005
Total			
<b>XI Profit/(loss) for the year from continuing operations (XI-XII)</b>		<b>1,16,90,570</b>	<b>1,25,25,454</b>
<b>Discontinued Operations</b>			
XII Profit/(loss) from discontinued operations		-	-
XIII Tax Expense of discontinued operations		-	-
XIV <b>Profit/(loss) from discontinued operations (XIV +XV)</b>		-	-
XV <b>XVII Profit/(loss) for the year (XIII+XVI)</b>		<b>1,16,90,570</b>	<b>1,25,25,454</b>
XVI <b>Other comprehensive income(OCI)</b>			
A (i) Items that will not be reclassified to profit or loss			
Re-measurement gains/ (losses) on defined benefit plans		-	17,98,982
Income tax effect relating to above item		-	(4,52,804)
B (i) Items that may be reclassified to profit or loss		-	-
(ii) Income tax on items that may be reclassified to profit or loss		-	-
<b>Total other comprehensive income</b>		-	<b>13,46,178</b>
<b>XVII Total comprehensive income for the year (V+ VI)</b>		<b>1,16,90,570</b>	<b>1,38,71,632</b>
XVIII <b>Earning per equity share (for Continuing Operatations)</b>			
(i) Basic		1.27	1.36
(ii) Diluted.		1.27	1.36
XIX <b>Earnings per equity share (for discontinued operation):</b>			
(i) Basic		0	0
(ii) Diluted.		0	0
XX <b>Earnings per equity share (for Continued and discontinued operation):</b>			
(i) Basic		1.27	1.36
(ii) Diluted.		1.27	1.36

The notes are an integral part of the financial statements



**For and on behalf of the Board of Directors**  
**VINEET LABORATORIES LIMITED**

Bh. Satyanarayana Raju  
Wholesale Director  
DIN:02697880

Place: Hyderabad  
Date: 10.11.2023

## VINEET LABORATORIES LIMITED

CIN:L24304TG2016PLC112888

SY. No. 11/A3, Eshwaramma Nilayam, Saheb Nagar, Kurdu Vill, Chintal Kunta, LB Nagar, Hyderabad, Telangana-500074, India.

## Statement of cash flows for the year ended 30 September 2023

Particulars	For the period ended 30 September 2023	For the year ended 31 March 2023
<b>A. Cash flow from/(used in) operating activities</b>		
<b>Profit/(Loss) before tax</b>	<b>1,26,21,948</b>	<b>2,02,99,213</b>
Adjustment for:		
Finance costs	1,98,34,104	3,38,01,876
Interest income	(21,233)	(12,30,137)
Fair value loss/(gain) on investments measured at FVTPL	(3,13,161)	22,000
Depreciation and amortisation expenses	1,22,05,764	2,37,26,002
Net foreign exchange (gain)/loss	-	33,72,000
<b>Operating Profit before Working Capital Changes</b>	<b>4,43,27,422</b>	<b>7,99,90,954</b>
<b>Changes in operating assets and liabilities</b>		
(Increase)/ decrease in trade receivables	(11,44,83,085)	50,69,600
(Increase)/ decrease in inventories	2,65,14,862	2,63,39,000
(Increase)/ decrease in other current assets	2,36,45,439	(30,04,000)
(Increase)/ decrease in other non current assets	(2,78,488)	(12,58,000)
(Increase)/ decrease in other financial assets	34,48,711	3,86,29,000
Increase/ (decrease) in trade payables	6,86,09,103	(26,25,51,000)
Increase/ (decrease) in provisions	(10,63,576)	17,90,000
Increase/ (decrease) in other liabilities	(11,47,32,855)	9,73,30,000
Increase/ (decrease) in other financial liabilities	6,51,800	(4,15,54,000)
<b>Cash generated from operations before tax</b>	<b>(6,33,60,667)</b>	<b>(6,62,70,000)</b>
Income tax paid, net	-	2,98,92,000
<b>Net cash from/(used in) operating activities</b>	<b>(6,33,60,667)</b>	<b>(9,61,62,000.00)</b>
<b>B. Cash flow from investing activities</b>		
Purchase of property plant and equipment	(73,58,433)	(7,63,42,000)
Interest received	21,233	12,30,000
Redemption/maturity of bank deposits (having original maturity of more than three months)	(48,68,208)	- 82,56,000
<b>Net cash from/(used in) investment activities</b>	<b>(1,22,05,408)</b>	<b>(6,68,56,000)</b>
<b>C. Cash flow from financing activities</b>		
(Repayment of)/ Proceeds from non-current borrowings	(53,68,583)	4,16,91,000
(Repayment of)/ Proceeds from current borrowings	10,06,75,479	40,61,000
Dividend paid	-	(92,19,000)
Interest paid	(1,98,34,104)	(3,38,02,000)
<b>Net cash from/(used in) financing activities</b>	<b>7,54,72,792</b>	<b>- 27,31,000</b>
<b>Net increase in cash and cash equivalents</b>	<b>(93,283)</b>	<b>(16,02,87,000)</b>
Cash and cash equivalents at the beginning of the period	63,07,376	16,65,94,000
<b>Cash and cash equivalents at the end of the period</b>	<b>62,14,093</b>	<b>63,07,000</b>

For and on Behalf of Board of Directors



Bh. Satyanarayana Raju  
Whole time Director  
DIN:02697880

Place:Hyderabad  
Date :10.11.2023



**Limited Review Report on Unaudited financial results of M/s Vineet Laboratories Limited**

Independent Auditor's Report on Quarterly and Year to Date Unaudited financial Results of M/s VINEET LABORATORIES LIMITED pursuant to regulation 33 of the SEBI (Listing and Obligations and Disclosure Requirements) Regulations, 2015.

**TO THE BOARD OF DIRECTORS OF Vineet Laboratories Limited**

We have reviewed the accompanying unaudited financial results of **M/s Vineet Laboratories Limited**, for the quarter ended 30 September 2023 and for the period from 1 April 2023 to 30 September 2023. This statement is the responsibility of the Company's Management and has been approved by the Board of Directors. Our responsibility is to issue a report on these financial statements based on our review.

We conducted our review of the Statement in accordance with the Standards on Review Engagement (SRE) 2410 'Review of Interim Financial Information Performed by the Independent Auditor of the entity' issued by the Institute of Chartered Accountants of India. This Standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial results are free from material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provide less assurance than an audit. We have not performed an audit and accordingly we do not express an audit opinion.

The procedures performed in a review are substantially less than those performed in an audit conducted in accordance with Standards on Auditing. Accordingly, we do not express an audit opinion on these financial results. Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying statement of unaudited financial results prepared in accordance with applicable accounting standards and other recognized accounting practices and that it contains any material misstatement.

Based on our review, nothing has come to our attention that causes us to believe that these financial statements do not give a true and fair view of the financial position of **M/s Vineet Laboratories Limited** as at 30 September 2023.

For NSVR & Associates LLP  
Chartered Accountants  
FRN: 008801S/S2000600



*V. G. dhara*  
V Gangadhara Rao, N  
Partner

M. No.219486  
UDIN: 23219486BGQCY2236  
Place: Hyderabad  
Date: 10-11-2023.

**NSVR & ASSOCIATES LLP**